SCHEMBL29035255

SCHEMBL29035255

CC(C)(C)OC(=O)N1CC(c2ccccc2)=C[C@H]1CO[Si](c1ccccc1)(c1ccccc1)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
UCHL1 P09936 2/20 0.37
SRC P12931 4/20 0.35
USP30 Q70CQ3 2/20 0.35
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34
SMYD2 Q9NRG4 1/20 0.34
HCRTR2 O43614 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
NR1H2 P55055 3/20 0.34
RXRA P19793 2/20 0.34
NR1H3 Q13133 2/20 0.34
PDK4 Q16654 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29035259 1.00 MEN1 (0.37) MEN1KMT2AUCHL1SRCUSP30
SCHEMBL29035412 0.93 MEN1 (0.36) MEN1KMT2AUCHL1USP30
SCHEMBL29035415 0.93 MEN1 (0.36) MEN1KMT2AUCHL1USP30
SCHEMBL25363576 0.91 DPP4 (0.41) MEN1KMT2AUCHL1GPR119NR1H2
SCHEMBL25363581 0.91 DPP4 (0.41) MEN1KMT2AUCHL1GPR119NR1H2
SCHEMBL30571864 0.91 GBA1 (0.40) MEN1KMT2AUCHL1CKS1BSKP1
SCHEMBL25364059 0.89 SMYD2 (0.36) SMYD2
SCHEMBL25364066 0.89 SMYD2 (0.36) SMYD2
SCHEMBL29035317 0.88 MEN1 (0.34) MEN1KMT2AUCHL1USP30SMYD2
SCHEMBL29035318 0.88 MEN1 (0.34) MEN1KMT2AUCHL1USP30SMYD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216946-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Achillion Pharmaceuticals, Inc. (US) 2023-08-02 EP disclosed
CN-116437913-A Pharmaceutical compounds for treating complement-mediated disorders 艾其林医药公司 2023-07-14 CN disclosed
WO-2022066774-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2022-03-31 WO disclosed